Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (121-130 of 288) with videos related to

Pageof 29
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in ItalyLuigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, et al.
AIDS (London, England)|March 4, 2006
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresMargaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, et al.
AIDS (London, England)|June 29, 2013
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyHans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin, et al.
The New Microbiologica|May 27, 2014
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirineSilvia Nozza, Laura Galli, Alba Bigoloni, et al.
The New Microbiologica|June 4, 2019
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study populationSimona Tecco, Maria R Parisi, Giorgio Gastaldi, et al.
Journal of the International AIDS Society|November 14, 2014
Predictors of lack of serological response to syphilis treatment in HIV-infected subjectsVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
BMC Infectious Diseases|November 18, 2017
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patientsNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
The New Microbiologica|August 6, 2013
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimensAntonella Castagna, Laura Galli, Nicola Gianotti, et al.
BMC Infectious Diseases|January 8, 2017
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patientsVincenzo Spagnuolo, Laura Galli, Andrea Poli, et al.
AIDS (London, England)|August 2, 2003
Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft, Lidia Ruiz, Peter Reiss, et al.
Pageof 29

Showing results (121-130 of 288) with videos related to

Sort By:
Pageof 29
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in ItalyLuigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, et al.
AIDS (London, England)|March 4, 2006
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failuresMargaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, et al.
AIDS (London, England)|June 29, 2013
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyHans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin, et al.
The New Microbiologica|May 27, 2014
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirineSilvia Nozza, Laura Galli, Alba Bigoloni, et al.
The New Microbiologica|June 4, 2019
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study populationSimona Tecco, Maria R Parisi, Giorgio Gastaldi, et al.
Journal of the International AIDS Society|November 14, 2014
Predictors of lack of serological response to syphilis treatment in HIV-infected subjectsVincenzo Spagnuolo, Andrea Poli, Laura Galli, et al.
BMC Infectious Diseases|November 18, 2017
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patientsNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
The New Microbiologica|August 6, 2013
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimensAntonella Castagna, Laura Galli, Nicola Gianotti, et al.
BMC Infectious Diseases|January 8, 2017
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patientsVincenzo Spagnuolo, Laura Galli, Andrea Poli, et al.
AIDS (London, England)|August 2, 2003
Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft, Lidia Ruiz, Peter Reiss, et al.
Pageof 29